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Abstract
Objectives Computed tomography perfusion (CTP) can pro-
vide information about angiogenesis and blood-flow char-
acteristics in tumours. [18F]Fluoro-2-deoxy-D-glucose–
positron emission tomography/computed tomography
(FDG-PET/CT) is one of the major oncological imaging
techniques which provides information about viability of
the tumour cell and partly also about its aggressiveness.
The aim of the study was to investigate the relationship
between FDG and CTP data in patients with head and neck
cancers.
Materials and methods Forty-one patients with a clinically
suspected head and neck cancer were prospectively includ-
ed. All patients underwent a combined PET/CT with an
integrated CTP examination in the area of the head and neck
tumour. CTP data (BF, BVandMTT) and PET data (SUVmax,
SUVmean, TLG, PETvol) were compared between tumours
and (1) healthy contralateral tissue, (2) inflammatory lesions,
(3) metastatic lymph nodes, and CTP data and PET data were
correlated in tumours.
Results Thirty-five patients had a head and neck cancer. All
CTP data were statistically different between tumours, in-
flammatory lesions, healthy tissue and metastatic lymph
nodes; PET/CT data were in part significantly different.
CTP and PET parameters were not significantly correlated.
Conclusion CTP and PET parameters were not significantly
correlated; thus, the additional CTP values provide addition-
al insights into tumour behaviour and their glycolytic status.
Key Points
• Computed tomography perfusion (CTP) can be performed
in combined positron emission tomography (PET)/CT.
• CTP in addition to PET provides additional insights into
tumour behaviour.
• CTP can possibly differentiate between head and neck
tumours and inflammatory lesions.
• PET/CTwith integrated CTP is possible without additional
contrast media.
Keywords CT-perfusion . PET/CT .PET/CTwith integrated
CT-perfusion .Headandneckcancer .Correlation of PET/CT
and CPT data
Introduction
Computed tomography perfusion (CTP) is now a robust,
non-invasive imaging tool which provides “functional”
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information within a primarily morphological imaging tech-
nique [1–6]. CTP has been evaluated in several tumour
entities and initial experiences are also available addressing
head and neck cancers. CTP has a positive correlation with
microvessel density and thus the blood flow in particular
was described as a useful parameter to reflect neoangio-
genesis in tumours [7].
Additionally, a possible prognostic impact was demonstrated
because CTP may predict response after chemotherapy
and progression-free survival after chemotherapy and
may be able to determine which patients will successfully
respond to chemotherapy [8–10].
[18F]Fluoro-2-deoxy-D-glucose–positron emission to-
mography/computed tomography imaging (FDG-PET/CT)
is a morphological and metabolic imaging tool for oncological
staging and therapy follow-up in a wide variety of
cancers [11–13]. FDG-PET/CT provides information about
the viability of the tumour, about the tumour aggressiveness
and proliferation in head and neck cancers.
Currently there is only very limited information about the
potential relation between FDG parameters (SUVmax and
SUVmean) and CTP parameters in head and neck cancers
[14, 15]. Additionally, there is no information about the
potential correlation between CTP values and additional
PET parameters (e.g. tumour lesion glycolysis (TLG) and
PETvol (tumour volume measured with PET) [16–19]. Al-
so, there is only very limited information about the relation-
ship among CTP values in ENT tumours and metastatic
lymph nodes, healthy contralateral tissue and no information
in comparison to inflammatory lesions [20, 21]. It is very
clear in theory that CTP and PET are measuring different
parts of tumour characteristics e.g. flow/perfusion and glucose
consumption, which only partly depends on the corresponding
flow. Thus, the aim of this study was (1) to compare and
correlate CTP parameters (blood flow (BF), blood volume
(BV) and mean transit time (MTT) and semi-quantitative
PET parameters (SUVmax, SUVmean, TLG and PET-based
lesion volume (PETvol)) in patients with head and neck
cancer and (2) to compare PET parameters and CTP parame-
ters between tumours, contralateral healthy tissue, metastatic
lymph nodes and inflammatory lesions.
Materials and methods
Patients
Forty-one patients were prospectively included between 09/
2008 and 01/2010 (mean age 61 years; range 43–78 years;
6 female, 35 male). All patients had a clinically suspected
head and neck cancer and all were referred for routine
primary staging by FDG-PET/CT to exclude distant metas-
tases in advanced disease. The CTP examination was fully
integrated into the standard contrast-enhanced PET/CT
procedure. No further selection was applied to the pa-
tient population.
All patients underwent endoscopic biopsy of the suspi-
cious head and neck lesions. Overall, 16 patients had a
carcinoma of the oropharynx (including cancer of the tonsils
and cancers of the base of the tongue), eight had a carcinoma
of the hypopharynx, four had a carcinoma of the larynx, five
had a carcinoma of the oral cavity (floor of the mouth and
tongue), one patient had a sinonasal cancer and one patient
had a squamous cell cancer of the mandible. All cancers were
head and neck squamous cell cancers (HNSCC). The other six
patients had inflammatory head and neck lesions. Twenty-four
patients had suspected lymph node metastases at the time of
study enrolment. Fifteen patients underwent additional neck
dissection during the clinical follow-up. Mean follow-up was
12 months (range 4–20 months). Two patients died during the
follow-up period. The study was performed in accordance
with the regulations of the local institutional review board
and ethics committee.Written, informed consent was obtained
from all patients before the examination and enrolment into
the study.
Integrated FDG-PET/CT imaging
All data were acquired on a combined PET/CT in-line
system (Discovery VCT, GE Healthcare, Milwaukee, WI,
USA). These dedicated systems integrate a last-generation,
full-ring PET with a multislice helical 64-slice CT and
permits the acquisition of co-registered CT and PET images
in one imaging procedure. The patients were instructed to
fast for 4 h prior to the examination. PET/CT imaging with
integrated CTP was started 60 min after the injection of a
standard dose of 300–340 MBq FDG. Blood sugar levels
were checked prior to the injection of the FDG. In addition,
an oral CT contrast agent (30 mL Gastrografin; Bayer
Schering Pharma, Berlin, Germany diluted with 970 mL
water) was administered during the uptake period. Patients
were examined in supine position. All patients received a
non-enhanced CT examination which was acquired with the
following parameters: 80 mA, 140 kV, 0.5-s tube rotation,
4.25-mm section thickness. The CT examinations were ac-
quired during shallow breathing in the head and neck area,
the thorax and the lower abdomen and during non-forced
expiration in the upper abdomen. The CT examinations
included the area from the head to the upper thighs.
The PET emission examination was acquired with an
acquisition time of 2 min per bed position after the low-dose
CT examination. Images (15 cm axial field-of-view (FOV)/
bed position) were reconstructed by using a standard fully 3D
iterative algorithm (ordered subset expectation maximisation,
OSEM: subsets, 28; iterations, 2; recon matrix, 128×128;
overlap, 9 slices).
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The images were reviewed directly on the PET/CT
console and the target lesions for the CTP examination
(including lymph nodes) were defined on the basis of
the focal glucose metabolism.
After target lesion definition, intravenous contrast injec-
tion was started by injecting a total dose of 70 mL contrast
media (Ultravist 370, Bayer Schering Pharma, Germany);
the first part for the CTP, the second part for completion of
routine contrast-enhanced CT (ceCT) of the neck and thorax
for fusion with the PET data. Seventy mL of contrast media
is the standard dose for imaging of the neck and thorax in
standard ceCT and ce-PET/CT in our department. First,
40 mL of contrast media (Ultravist 370, Bayer Schering
Healthcare, Germany) was applied at a flow of 5 mL/s via
a cubital vein. This represents the default protocol as sug-
gested by the vendor. After a 5-s delay, the perfusion data
were acquired for 50 s in the area of interest (1 s rotations
time with 1 image/s, cine duration 50 s, 8 slices, 5 mm slice
thickness, 80 mA, 80 kV). Thus, an anatomical cranio-
caudal coverage of 4 cm was achieved for the perfusion
examination of the target ENT lesion. The first contrast
media bolus was followed by a saline flush (20 mL,
5 mL/s). Since the system did no allow for a shuttle
mode at the time of the study, a 4-cm FOV for perfusion
imaging represents the maximum coverage possible with the
chosen time resolution.
Directly after the perfusion, a second bolus of another
30 mL of contrast media (Ultravist 370, Bayer Schering
Healthcare, Germany) was applied at 4 ml/s followed by a
saline flush of 30 mL to ensure full diagnostic ceCT data of
the neck and thorax because all CTP examinations were
fully integrated into the routine, clinical cePET/CT staging
and re-staging examination.
The non-enhanced low-dose CT data (4.25 mm slices)
were used for attenuation correction, and images were
reconstructed by using OSEM. For image co-registration
and analysis, all reconstructed images (non-enhanced CT,
ceCT, CTP images) were then transferred to a commercially
available workstation (Advantage Workstation, 4.4, GE
Healthcare, Milwaukee, WI, USA), where image data were
evaluated in all three planes as a single procedure and in a
co-registered mode. CTP data were evaluated using com-
mercially available perfusion software with a deconvolution
method to calculate the perfusion values (CT-Perfusion 3,
Body-Protocol; see also “Image evaluation” below).
Image evaluation
CTP evaluation
CTP data were evaluated by a dual-board-certified nuclear
medicine physician/radiologist using the aforementioned
default body protocol of the commercially available CTP
software. A threshold of −3 to −120 HU was defined for soft
tissue visualization. The arterial input was defined by a
circular automated region of interest (ROI) in one of the
cervical arteries within the FOV on the contralateral side of
the target lesion. The calculated time–enhancement curve
and the parametric imaging maps for BF (mL/100 mg tissue/
min), BV (mL/100 mg tissue) and MTT (seconds) were
automatically calculated by the software. The permeability
surface (PS) was not calculated (short study protocol). A
freehand ROI defined by the margin of the target ENT
lesion was placed in every slice of the perfusion volume
(4 cm coverage, 5 mm slice thickness). In cases when a
FDG-positive lymph node was detected within the FOV,
another ROI defined by the margins of the lymph node
was placed in the perfusion volume, too (11 patients). The
reason was to compare the perfusion values of metastatic
lymph nodes with the perfusion values of the primary tu-
mour because other, larger studies already investigated the
comparison of metastatic vs. non-metastatic lymph nodes
(see “Discussion”).
A third ROI was positioned within the contralateral
healthy ENT tissue (the opposite side pair of the same organ
if applicable or contralateral side) to compare perfusion
values of malignant and non-malignant ENT tissue [22]
Several other publications already evaluated tumours vs.
normal muscle. Thus, because this concept already proved
to be reliable for general comparison reasons, we chose
another evaluation specifically for ENT tissue comparisons.
PET/CT data evaluation
PET data were evaluated by another dual-board-certified
nuclear medicine physician/radiologist. A cubic VOI (volume
of interest) was placed over the primary target ENT lesion on
the PET/CT images and over the FDG-positive lymph node if
present within the CTP-FOV. The software then creates an
additional threshold delimited VOI within the aforementioned
cubic VOI boundaries which in turn delineates the lesion. The
threshold taken for the second VOI was 42 % of maximum
voxel (default by software).
The VOI automatically calculates the standard uptake
values (SUVmax, SUVmean), TLG and the volume of the
lesion (PETvol) based on the FDG uptake.
Statistical analysis
The differences between the CTP values as well as PET
values of ENT tumours, healthy contralateral ENT tissue,
inflammatory lesions and metastatic lymph nodes were
tested for statistical significance with the Mann–Whitney
test. A p value less than 0.05 was considered statisti-
cally significant.
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The correlation between all CTP data and all evaluated
PET data were calculated using Pearson correlation first.
Additionally, Spearman’s rho, a non-parametric rank corre-
lation coefficient, was used. A P value of less than 0.01 was
considered statistically significant.
To demonstrate supplemental confidence intervals, boot-
strap confidence intervals were calculated, too. Statistical
analyses were performed with SPSS statistical software
(version 16.0.1, SPSS Inc, Chicago, Ill).
Results
Patients
In 35 of 41 patients a malignant head and neck cancer was
confirmed by histopathology (clinical stage, Table 1). In 20
patients, contralateral, healthy ENT tissue could be mea-
sured. In the remaining 15 patients, the ENT tumour was
suspected to or crossed the midline, making contralateral
measurements possibly not reliable. In six patients, histopa-
thology showed inflammatory lesions. In 11 out of 24
patients with suspected lymph nodes metastases, malignant
lymph nodes were located within in the CTP volume.
CTP values of malignant lesions, contralateral healthy ENT
tissue, metastatic lymph nodes and inflammatory lesions
CTP values of the confirmed malignant tumours and con-
firmed inflammatory lesions were compared. Mean BF of
malignant tumours was 89.6 mL/100 mg/min, mean BV was
5.7 mL/100 mg and mean MTT was 7.4 s compared to
68.6 mL/100 mg/min, 4.0 mL/100 mg and 5.5 s in inflamma-
tory lesions. Interestingly, the MTTs of inflammatory lesion
were lower than for the malignant lesions.
Comparisons of BF, BV and MTT of malignant and
inflammatory lesions were statistically significant different
(P00.0001, P00.0012, P<0.0001, respectively) (Fig. 1).
The CTP values of healthy contralateral ENT tissue
showed a mean BF of 42.1 mL/100 mg/min, a mean BV of
3.4 mL/100 mg and a mean MTT of 10.8 s. Comparisons of
BF, BVand MTT of malignant ENT lesions and contralateral
healthy ENT tissue were statistically significant different
(P<0.0001, P00.0001, P00.03, respectively).
The CTP values of metastatic lymph nodes showed a
mean BF of 93.4 mL/100 mg/min, a mean BV of 4.4 mL/
100 mg and a mean MTT of 4.5 s. All parameters were
statistically significant different when compared to the tumour
lesions (all P≤0.002) (Fig. 2). Again, MTT of metastatic
lymph nodes was lower than for the malignant lesions.
PET values of malignant lesions, contralateral healthy ENT
tissue, metastatic lymph nodes and inflammatory lesions
PET values of the confirmed malignant tumours and con-
firmed inflammatory lesions were compared. As expected,
SUVmax and SUVmean were statistically significant
different (tumour vs. inflammation: 10.2 vs. 5.4 and
6.3 vs. 3.2, P00.02; P00.03).
When comparing the TLG, no statistically significant
difference was found between tumours and inflammatory
ENT tissue (TLG tumour, 94101; TLG inflammation,
49183; P00.8). No statistical difference was found when
comparing the PETvol between tumours and inflammatory
ENT tissue (PETvol tumour, 14.0 cm3; PETvol inflammation,
18.0 cm3; P00.1)
The PET values of healthy contralateral ENT tissue
showed a mean SUVmax of 3.3, a mean SUVmean of 2.1,
a mean TLG of 19328 and a PETvol of 11.8 cm3. Comparisons
of PET parameters of malignant ENT lesions and contralateral
healthy ENT tissue were in part statistically significant different
(SUVmax/mean, P<0.0001; TLG, P00.001; PETvol, P00.8)
(Fig. 3). Thus, on the basis of PETvol no differentiation could
be made between healthy contralateral ENT tissue and
tumours.
The PET values of metastatic lymph nodes showed a
mean SUVmax of 6.9, a mean SUVmean of 4.8, a mean
TLG of 57563 and a PETvol of 9.3 cm3. No further statis-
tical evaluation was applied (see “Discussion”).
All CTP data and PET data of malignant lesions, meta-
static lymph nodes and inflammatory lesions are listed in
Table 2.
Correlation of CTP data and PET data
All perfusion data (BF, BV, MTT) were correlated with all
acquired PET parameters (SUVmax, SUVmean, TLG and
PETvol). No obvious statistically significant relations could
be established between the evaluated CTP parameters and
corresponding PET parameters (Table 3). However, boot-
strap confidence intervals for correlation of BF and SUV-
max as well as BF and SUVmean showed upper limits of
confidence intervals of 0.519 and 0.528. Thus, there might
possibly be a fair correlation for those parameters in this
patient population.
Table 1 Clinical stage of patients with confirmed malignant tumours
Clinical stage (n035)
T 5×T1 11×T2 7×T3 12×T4
N 11×N0 3×N1 4×N2a 3×N3
9×N2b
5×N2c
M All patients M0 at time of study enrolment
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Discussion
Currently there is only limited experience available concerning
the differences in perfusion characteristics between ENT
tumours and healthy contralateral ENT tissues, inflammatory
lesions and metastatic lymph nodes and the correlation of PET
parameters and CTP parameters in those patients. So far, this is
one of the largest studies evaluating PET/CT with integrated
CTP in head and neck cancer patients. When comparing CTP
parameters between tumours and inflammatory lesions, healthy
contralateral tissue and metastatic lymph nodes significant dif-
ferences were found. PET parameters between tumours and
inflammatory lesions, healthy contralateral tissue and meta-
static lymph nodes were in part significantly different. No
significant correlations were found between CTP parameters
and PET parameters.
General aspects
Several issues have to be addressed when implementing a
CTP protocol into a whole-body FDG-PET/CT protocol.
Such an advanced imaging concept should, ideally, provide
additional useful parameters at equal or only minimally
higher procedure complexity at the same time. The
advantage of an integrated PET/CT approach is that
the PET component already indicates the location of
the pathology in question and the perfusion examination
can be planned accordingly; thus, unlike other dedicated
CTP research studies, no additional CT localizer is
needed. Furthermore, when integrated in a PET/CT ex-
amination, whole-body staging and information about
distant metastases are available in one step.
Tumour vs. healthy contralateral tissue
We found significant differences in CTP values between the
primary tumour lesion and the contralateral healthy tissue.
This is in line with the results of Faggioni and co-workers
who were the first to show that CTP values differ not only
between tumours and muscle tissue, but also between tu-
mour lesions and the contralateral healthy side [20]. These
characteristics and perfusion values are based on the
Fig. 1 Top row 3D MIP PET, axial contrast-enhanced CT, axial
contrast-enhanced PET/CT. Bottom row axial images of the same area
displayed as BF, BV and MTT. A 74-year-old male patient with a
suspected malignant tumour of the right submandibular gland (white
arrow). The CT shows an unclear lesion of the right submandibular
gland, the PET/CT shows mild FDG uptake. The perfusion images
show mildly elevated BF and BV compared to mean tumour values,
but lower MTT. The lesion turned out to be inflammatory
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different tissue architecture of the different head and neck
tissue compartments (e.g. lymphoid tissue) and underline
the ability of CTP to distinguish different types of tissue.
The reason for the significant different perfusion parameters
compared to tumours is the increased perfusion demand
based on an enlarged neovascular bed evoked by tumoral
neoangiogenesis with consecutive intratumoral arteriove-
nous shunts [20, 23]. This physiological concept has been
also demonstrated by the correlation between BF (and ad-
ditionally but not significantly so, BV) and tumour micro-
vessel density [23, 24]. Concerning the PET parameter it
well known that PET/CT can differentiate between non-
malignant tissue and malignant ENT lesions. However, the
PETvol was not statistically different between non-
malignant tissue and malignant lesions. This is probably
due to inability of the software to differentiate subtle differ-
ences of tissue with comparable metabolic activity which is
evident in the head and neck area (e.g. muscle activity,
lymphoid tissue) and thus too large a volume is calculated.
Tumour vs. inflammation
We found significant differences in CTP values between the
primary tumour lesion and the inflammatory ENT lesions.
Diagnostically, differentiation of malignant and non-
malignant lesions in the ENT area is challenging because
several anatomical structures are located tightly beneath
each other. It had already been demonstrated, however,
that CTP might be able to distinguish between inflam-
mation and tumour in other entities [25]. Those results
indicate that CTP is a very sensitive method concerning
this differentiation. An interesting aspect is that the
MTTs of inflammatory lesions were lower than those
of malignant lesions. Generally, one would expect faster
flow in tumour lesions than in inflammation tissue.
However, a possible interpretation of this phenomenon
might be that tumour-related necrosis in malignant
lesions prolongs the MTT, whereas in inflammatory
lesions tissue structure and architecture are intact.
Fig. 2 Top row 3D MIP PET, axial contrast enhanced CT, axial
contrast-enhanced PET/CT. Bottom row axial images of the same area
displayed as BF, BV and MTT. A 70-year-old male patient with a
suspected malignant tumour of the base of the tongue (grey arrows).
The patient additionally had a right cervical lymph node metastases
within the CTP-FOV (white arrows) and another large left cervical
lymph node metastasis (black arrow, not within CTP-FOV). CT shows
a large contrast-enhancing mass at the right base of the tongue and a
pathologically and partly necrotic lymph node right cervically, the
PET/CT shows elevated FDG uptake in those lesions. The perfusion
images show highly elevated BF and BV and a decreased MTT
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PET/CT is known to be less specific concerning the
differentiation of inflammatory lesions and tumours, espe-
cially in the head and neck area [26]. We found statistically
significant differences between tumours and inflammation
in SUVmax and SUVmean, whereas the TLG and the PET-
vol were not able to distinguish either entity. The PETvol
measures the volume of increased metabolic activity and
therefore it is coherent that it cannot differentiate between
the reason for increased metabolic activity—whether derived
from tumour or inflammation. It has been proven that the TLG
might be a useful prognostic parameter in different tumours
[16–19]. However, since the TLG is influenced by the PET-
vol, it might not be useful for differentiation between tumours
and inflammation.
Tumour vs. metastatic lymph nodes
Trojanowska and co-workers found in a recent study that
CTP is be able to distinguish between malignant and benign
lymph nodes in patients with ENT cancer [21]. BF, BV and
Fig. 3 Top row 3D MIP PET, axial contrast-enhanced CT, axial
contrast-enhanced PET/CT. Bottom row axial images of the same area
displayed as BF, BV and MTT. A 72-year-old male patient with
suspected laryngeal cancer of the anterior commissure (white arrows).
The CT shows a focal thickening of the anterior vocal cords bilaterally,
the PET/CT shows the corresponding elevated FDG uptake. The per-
fusion images show highly elevated BF and BV and a decreased MTT
Table 2 Comparison of mean
CTP values and mean PET val-
ues of tumours, healthy contra-
lateral side, inflammatory
lesions and lymph nodes
Malignant tumour Inflammatory lesions Contralateral side Lymph nodes
BF (mL/100 mg/min) 89.6 68.6 42.1 93.4
BV (mL/100 mg) 5.7 4.0 3.4 4.4
MTT (s) 7.4 5.5 10.8 4.5
SUVmax 10.2 5.4 3.3 6.9
SUVmean 6.3 3.2 2.1 4.9
TLG 94101 49183 19328 57563
PETvol (cm3) 14 18 11.8 9.3
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PS (permeability surface area) were statistically different
between these two groups, whereas MTT was not signifi-
cantly different. While the BF in our group was lower than
that published in the aforementioned study, the MTT and
BV were quite similar. We had a much smaller group of
lymph nodes within the FOV and thus we did not compare
metastatic lymph nodes vs. non-metastatic lymph nodes in
ENT cancer patients. However, it is an interesting finding
that all CTP parameters in our study were significantly
different between malignant primary lesions and metastatic
lymph nodes. A possible reason is the amount of malignant cells
within a lymph node vs. the number ofmalignant cells within the
primary tumour and the consequent demand forblood supply.An
interesting aspect might be that metastatic lymph nodes in our
studyhadahighBF,alowBVandafastMTT.Thismightbepartly
attributed to HPV-positive lymph nodes. Those nodes are
generally large, but do contain a large amount of cystic/necrotic
material and thus the SUV can be very low [27].
We did not evaluate PS because we used too short a
protocol to measure stable PS values. Again, the MTT in
our study was lower in the metastatic lymph nodes than in
the primary malignant lesion.
We did not compare the PET/CT data between the primary
malignant lesion and metastatic lymph nodes, because those
PET parameters in part depend on lesion size. However, it has
already been shown that metastatic lymph nodes might have
different SUV values than the primary tumour [28].
Correlation of PET and CTP values
We did not find obvious correlations between CTP values
and PET values. But, the confidence intervals for the
Table 3 Correlation of CTP da-
ta and PET data. Correlations of
CTP data (BF, BV, MTT) with
PET data (SUVmax, SUVmean,
TLG). No obvious correlation
was found. On the basis of the
given confidence intervals, a
correlation between SUVmax as
well as SUVmean and BF of up
to 0.5 might be possible
BF (mL/100 mg/min) BV (mL/100 mg) MTT (s)
SUVmax Pearson correlation 0.070 0.064 0.239
Sig. (2-tailed) 0.694 0.719 0.174
Spearman’s rho 0.182 0.005 0.145
Sig. (2-tailed) 0.295 0.978 0.405
Bootstrap
Std. error 0.178 0.184 0.175
95 % CI lower 0.186 0.362 0.457
Upper 0.519 0.345 0.198
SUVmean Pearson correlation 0.060 0.057 0.226
Sig. (2-tailed) 0.736 0.749 0.198
Spearman’s rho 0.176 0.016 0.140
Sig. (2-tailed) 0.313 0.929 0.422
Bootstrap
Std. error 0.182 187 0.179
95 % CI lower 0.199 0.377 0.457
Upper 0.528 0.337 0.206
TLG Pearson correlation 0.006 0.128 0.151
Sig. (2-tailed) 0.974 0.470 0.393
Spearman’s rho 0.023 0.118 0.020
Sig. (2-tailed) 0.895 0.499 0.908
Bootstrap
Std. error 0.191 0.200 0.178
95 % CI lower 0.404 0.519 0.367
Upper 0.367 0.300 0.326
PETvol Pearson correlation 0.112 0.237 0.020
Sig. (2-tailed) 0.529 0.177 0.910
Spearman’s rho 0.090 0.182 0.028
Sig. (2-tailed) 0.606 0.296 0.874
Bootstrap
Std. error 0.186 0.199 0.164
95 % CI lower 0.467 0.571 0.288
Upper 0.301 0.236 0.337
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correlation of SUVmax and BF as well as SUVmean and BF
showed an upper limit of 0.5 and therefore there might be a
possible correlation.
One other publication already indicated that there might
be significant correlations between SUVmax and BF as well
as SUVmean and BF in patients with ENT cancer [14].
Other publications indicated that coupling between SUV
and BF might be evident in other lesions too [3, 4, 29].
The physiological concept of elevated cell metabolism in-
duced by increased blood supply is generally accepted and
has been proved in different tissues. However, in tumours an
elevated SUV might be the expression of different intracel-
lular pathways. Increased glycolysis can be a response to an
increase in energy demand, increase of cell proliferation,
increase of synthesis rates or activation of specific oncogenic
pathways. Thus, the SUV itself is already a balanced signal
and comprised of different components. Those changes might
additionally also happen in the presence of an inadequate
oxygen feed, because tumours can have continued high gly-
colytic rates even with inadequate oxygen supply (Warburg
effect) [30, 31]. Several studies furthermore concluded that
increased consumption of glucose in tumours/metastatic
lesions is not only used for substantial energy production via
Embden–Meyerhoff glycolysis, but rather for production of
acids. In consequence, acids are believed to give cancer cells a
competitive advantage for invasion. Alternatively, the glucose
might be also used for generation of anabolic precursors [32].
However, coupling and significant correlation might depend
on the tumour entity and glycolytic status of the tumour.
Hirasawa and co-workers found in a small patient population
with suspected head and neck tumours that BF and SUV
measurement were inversely correlated [15]. They concluded
that this might be attributed to anaerobic glycolysis which is
contradictory with the results mentioned above in head and
neck cancers and other tumour entities. Overall, the additional
CTP values can provide additional insights into tumour be-
haviour and their glycolytic status.
Significant differences between our study and the afore-
mentioned trials have to be mentioned and might partly
explain the differences in our results. Our current study
investigated the biggest patient population with ENT can-
cers to date. Furthermore, the perfusion volume was as twice
as large (64-slice CT, 4 cm CTP coverage) as in the other
studies and this might have contributed additionally to those
differences.
The TLG represents a combination of the lesion’s volume
and the average SUVand is considered as a useful parameter
to represent the overall tumour burden. It has been shown to
be of prognostic value in several tumour entities [17, 19, 33].
We found no significant correlations in our study between
TLG and CTP values and the confidence intervals showed
only low possible correlations. Thus, no obvious advantage
when comparing CTP values to the “routine” SUVmax
evaluation could be demonstrated. A possible advantage
concerning its prognostic value vs. or combined with CTP
values (which can also have prognostic value) has to be
investigated.
Limitations
A limitation is certainly the somewhat limited number of
patients overall and the limited number of patients having
metastatic lymph nodes within the CTP FOV. However, the
CTP values of metastatic lymph nodes and inflammatory
lesions are comparable with the those in the literature.
Another limitation is the diverse group of tumour entities
evaluated. Most of the available CTP studies used a 50-s
CTP protocol and also evaluated the permeability surface
product (PS) [8, 14, 22, 34]. We chose not to further
discuss that parameter because PS is typically measured
after 90 s based on the intravessel time of the contrast
media. Thus, the PS might be compromised by the short
examination time.
We did not evaluate the prognostic impact of the CTP and
PET values because only a small proportion of the patients
underwent the same treatment pathway. However, the prog-
nostic impact of several PET parameters has already been
evaluated [28]. There are also several indicators that CTP
can have prognostic impact in several tumour entities [10,
34, 35].
Outlook
Since more hybrid PET/CT systems with perfusion capabil-
ities are currently being installed, combined PET/CTP might
find its way into clinical routine to support the diagnosis of
malignant versus non-malignant lesions. However, to
achieve such a routine clinical level, it is first mandatory
to find a cut-off value for the differentiation of malignant vs.
non-malignant lesions based on perfusion parameters. How-
ever, to find such a generally accepted cut-off is complicat-
ed, because there are currently no guidelines and generally
accepted technical specifications on how to perform perfu-
sion imaging. Thus, such a cut-off value currently can only
be used in a single centre where it is evaluated. In our study,
the mean BF for malignant lesions was 89.6 mL/100 mg/
min and 68.6 mL/100 mg/min for inflammatory lesions.
Since the BF for malignant lesions was comparable with
other studies available in the literature (as discussed above),
those values around 90 mL/100 mg/min (when evaluated
with the same post-processing software) might support the
diagnosis of malignant rather than non-malignant ENT
lesions in questionable cases when the SUVmax does not
clearly indicate malignancy. However, we did not apply any
further ROC analysis because we feel that the patient
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number for that is somehow limited, especially concerning
the inflammatory lesions.
In conclusion, PET/CTP can be integrated into a routine,
contrast-enhanced PET/CT protocol for staging in ENT
cancers without additional use of contrast media. CTP and
PET parameters were not significantly correlated and hence
the additional CTP values can provide additional insights
into tumour behaviour and their glycolytic status. Metastatic
lymph nodes have high CTP values and can be possibly
differentiated from the primary tumour lesion. The primary
tumour and inflammatory lesions can be differentiated by
CTP values as well as partially by PET measurement. Fur-
ther research and especially larger standardized studies are
needed concerning combined ratios of CTP and PET values
for a better understanding of the relation between tumour
perfusion and glycolytic rate.
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